GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Healios KK 4593.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

224

+0.45%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥104.0m

FY2016FY2025

Net income

−¥2.22bn

FY2016FY2025

Free cash flow

−¥3.33bn

FY2016FY2025

Shareholders' equity

¥4.89bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue¥104.0m¥560.0m¥121.0m¥90.0m¥41.0m¥27.0m¥89.0m—¥27.7m¥77.6m
Research and development¥2.02bn¥1.96bn¥2.30bn¥3.81bn¥3.70bn¥2.99bn¥3.22bn¥4.27bn¥1.73bn¥2.96bn
Operating income−¥3.40bn−¥2.85bn−¥3.38bn−¥5.18bn−¥5.38bn−¥4.20bn−¥4.31bn−¥5.08bn−¥2.35bn−¥3.51bn
Net income−¥2.22bn−¥4.24bn−¥3.82bn−¥5.17bn−¥4.91bn−¥5.51bn−¥4.41bn−¥5.10bn−¥1.78bn−¥3.43bn
Diluted earnings per share-21.71-46.96-51.29-84.60-85.60-107.23-86.95-103.44-36.11-83.46

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets¥17.05bn¥14.19bn¥15.15bn¥15.03bn¥23.97bn¥23.17bn¥25.59bn¥14.98bn¥19.70bn¥9.17bn
Cash and short-term investments¥5.68bn¥3.67bn¥6.72bn¥7.32bn¥15.13bn¥13.92bn¥18.30bn¥11.63bn¥19.04bn¥7.83bn
Total liabilities¥12.15bn¥12.11bn¥11.29bn¥10.65bn¥15.33bn¥15.32bn¥13.25bn¥4.20bn¥3.53bn¥3.18bn
Debt¥2.61bn¥2.66bn¥4.53bn¥7.98bn¥12.22bn¥11.40bn¥10.24bn¥2.70bn¥2.37bn¥2.50bn
Shareholders' equity¥4.89bn¥2.06bn¥3.86bn¥4.38bn¥8.64bn¥7.84bn¥12.34bn¥10.78bn¥16.16bn¥5.99bn
Shares outstanding102m90m75m61m57m51m51m49m49m41m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−¥3.17bn−¥1.82bn−¥2.82bn−¥4.60bn−¥5.09bn−¥3.94bn−¥4.97bn−¥5.15bn−¥1.76bn−¥3.78bn
Capital spending−¥168.0m−¥15.0m−¥28.0m−¥262.0m−¥300.0m−¥313.0m−¥103.0m−¥97.0m−¥72.1m−¥92.5m
Free cash flow−¥3.33bn−¥1.83bn−¥2.85bn−¥4.86bn−¥5.39bn−¥4.26bn−¥5.07bn−¥5.25bn−¥1.83bn−¥3.88bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥7.0m¥8.0m¥25.0m¥19.0m¥22.0m¥38.0m¥18.0m¥34.0m
Operating income−¥1.28bn−¥1.14bn−¥1.01bn−¥764.0m−¥865.0m−¥763.0m−¥870.0m−¥664.0m
Net income¥1.19bn−¥3.48bn¥1.93bn¥563.0m−¥2.15bn−¥2.56bn¥256.0m−¥1.53bn
Diluted earnings per share8.83-25.7618.895.51-21.04-25.082.84-17.00
Cash from operations−¥1.24bn−¥1.27bn−¥838.0m−¥750.0m−¥815.0m−¥762.0m−¥578.0m−¥141.0m
Capital spending−¥96.0m−¥36.0m−¥93.0m−¥58.0m−¥5.0m−¥12.0m−¥2.0m−¥4.0m
Free cash flow−¥1.34bn−¥1.31bn−¥931.0m−¥808.0m−¥820.0m−¥774.0m−¥580.0m−¥145.0m
Total assets¥23.12bn¥23.48bn¥17.05bn¥17.33bn¥16.84bn¥15.69bn¥14.19bn¥12.74bn
Cash and short-term investments¥9.07bn¥10.87bn¥5.68bn¥6.50bn¥6.25bn¥5.46bn¥3.67bn¥4.53bn
Debt¥2.99bn¥590.0m¥2.32bn¥132.0m¥2.17bn¥118.0m¥117.0m¥22.0m
Shareholders' equity¥8.77bn¥7.55bn¥4.89bn¥2.94bn¥1.25bn¥1.96bn¥2.06bn¥1.71bn

Financial ratios

Data as of 15 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-3272.1%-508.0%-2792.6%-5751.1%-13131.7%-15544.4%
Net margin-2131.7%-756.3%-3159.5%-5744.4%-11980.5%-20418.5%
Return on equity-45.3%-205.3%-99.1%-118.0%-56.9%-70.3%
Return on assets-13.0%-29.8%-25.2%-34.4%-20.5%-23.8%
Free cash flow yield-10.1%-6.9%-12.9%-24.5%-28.8%-24.4%
Revenue growth-81.4%362.8%34.4%119.5%51.9%-69.7%
Earnings growth-47.7%10.8%-26.1%5.3%-10.9%25.0%
Current ratio2.00x1.28x1.49x2.22x2.72x5.59x
Debt to equity0.45x1.05x1.18x1.60x1.35x1.42x
Equity ratio28.7%14.5%25.4%29.1%36.0%33.9%
Interest coverage-17.02x-1.79x-4.80x-10.35x-6.71x-3.55x
R&D as a share of sales1946.2%350.0%1904.1%4231.1%9024.4%11059.3%
Buybacks as a share of market value-13.2%-21.0%-22.0%-6.5%-11.6%-1.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.9%31.0%0.6%
Operating income-13.0%-4.1%12.4%
Net income-24.6%-16.7%8.8%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-941.0%-1691.8%-2585.8%—
Net margin-971.7%-1765.1%-2743.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-12.6-3.8-3.2-3.2-15.0-18.3-17.2-16.1-53.7-26.0
Price to sales269.028.5101.7182.0——————

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.